Therefore, we speculate that the PI3K/Akt pathway serves as a vital pathway in the anticancer activity of baicalein combined with almonertinib in almonertinib-resistant NSCLC cells. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.